In some sense, every person’s cancer is unique. However, for several reasons, patients are often treated in a one-size-fits-all manner, usually based on where their cancer is. http://www.cancerresearch.org
Fortunately, recent advances in technology as well as treatments like immunotherapy, are starting to enable doctors to better tailor their treatments to their individual patients, based on what’s most likely to work in their specific circumstances.
In this webinar for patients and caregivers, Patrick Hwu, M.D., of the University of Texas MD Anderson Cancer Center, discusses the advances in personalized treatment approaches for cancer. In particular, he highlights the promise and potential of combination immunotherapies and how biomarkers can be used to guide these strategies. In addition, Dr. Hwu also discusses the challenges that must be overcome in order to realize the potential of these personalized approaches.
Patrick Hwu, M.D., is the head of the Division of Cancer Medicine, the co-director of the Center for Cancer Immunology Research, and the Sheikh Mohammed Bin Zayed Al Nahyan Distinguished University Chair at the University of Texas MD Anderson Cancer Center in Houston, TX.
As both a practicing oncologist and a tumor immunology researcher, Dr. Hwu’s goal is to translate basic immunological concepts into treatments that can benefit patients in the clinic. In pursuit of that goal, his work has provided important insights into our understanding of the relationship between tumors and the immune system, many of which have helped to advance clinical immunotherapy strategies, especially adoptive cell-based approaches. Most recently, he has focused on combining cellular and checkpoint immunotherapies, in addition to rational combinations involving other agents, in order to improve patient survival.
The “Cancer Immunotherapy and You” webinar series is produced by the Cancer Research Institute and is hosted by our science writer, Arthur Brodsky, Ph.D. The 2019 series is made possible with generous support from Bristol-Myers Squibb and Cellectis.